UPDATES

Abstract
Some diabetes drugs ‘linked to lower risk of kidney stones and gout’, study finds
Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of recurrent kidney stones and gout flare-ups, finds a study from Canada published by The BMJ.
Kidney stones (nephrolithiasis) and gout are both common, recurrent, extremely painful conditions, especially in patients with type 2 diabetes. They also incur substantial healthcare costs.
As well as treating type 2 diabetes, trials have shown that SGLT-2 inhibitors can also lower the risk of heart failure and kidney disease, but their effect on recurrent kidney stones and gout flare-ups is still uncertain.
To explore this further, researchers set out to compare the effects of SGLT-2 inhibitors on risk of recurrent kidney stones and gout with two other groups of diabetes drugs known as GLP-1 receptor agonists and DPP-4 inhibitors.
Their findings are based on data for 20 146 adults (average age 65; 73% men) with type 2 diabetes and a history of kidney stones, gout, or both, who had not previously used SGLT-2 inhibitors, GLP-1 receptor agonists or DPP-4 inhibitors.
Register now to continue reading
Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to our clinical or professional articles
-
New content and clinical newsletter updates each month